Yazar "Aras, Merih Reis" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients
    (AKAD DOKTORLAR YAYINEVI, 2023) Tığlıoğlu, Mesut; Albayrak, Murat; Tığlıoğlu, Pınar; Yıldız, Abdulkerim; Doğan, Servihan; Afacan Öztürk, Hacer Berna; Maral, Senem; Sağlam, Buğra; Aras, Merih Reis; Dilek, İmdat
    Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and patients older than 65 years have a poor prognosis. Patient-related factors, such as comorbid conditions that affect performance status, and insufficient organ functions, explain why elderly patients have a worse prognosis. The Charlson Comorbidity Index (CCI), is used to predict prognosis according to comorbidities. This retrospective study was conducted on patients diagnosed with AML between 2010 and 2019. Patients >60 years were included. Demographic information, comorbidities, CCI, ECOG ( Eastern Cooperative Oncology Group) score, cytogenetic characteristics, treatment regimens, treatment response, follow-up periods were recorded for all patients. Evaluation was made of a total of 82 patients with a mean age of 71.18 ± 7.67. The median follow-up was 6.7 months. The median number of comorbidities was 1 [0.0-4.0] with the median CCI score of 3 [2.0-6.0]. Median overall survival (OS) was 7.0 months [3.1-10.8] and PFS was 6.8 months [3.6-10.0]. As the median CCI score was 3, patients were divided into two groups as CCI > 3 and CCI ? 3. Age, gender, ECOG, cytogenetic risk profile, first-line treatment and CR1 achievement status were all similar in both groups (p > 0.05). Patients with CCI > 3 had significantly shorter OS than patients with CCI ? 3 (3.6 months [0.3-29.3] vs 8.6 months [0.2-60.2], p= 0.049). The results of the current study demonstrated that CCI, can be used as a prognostic index in elderly patients with AML independently of other patient and disease-related characteristics.
  • Küçük Resim
    Öğe
    The Utility of CONUT Score in Indolent Lymphoma Patients
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2023) Tığlıoğlu, Mesut; Afacan Öztürk, Hacer Berna; Yıldız, Abdulkerim; Tığlıoğlu, Pınar; Yılmaz, Fatma; Aras, Merih Reis; Albayrak, Meryem
    Background and Aim: Similar to the uncertainties in the treatment criteria for indolent non-Hodgkin lymphoma (iNHL), the prognostic criteria have not been fully clarified. The Controlled Nutritional Status (CONUT) score is not only used as a predictor of malnutrition but also indicates prognosis in many chronic or malignant diseases. The aim of this study is to investigate the predictive and prognostic significance of the CONUT score in patients with iNHL. Patients and Methods: A retrospective evaluation was made of 109 patients with iNHL. The CONUT scores of the patients were compared between those with an indication for treatment and those followed without treatment. The same analysis was performed between patients who developed relapse after treatment. Survival analysis was performed on all patients, and associations between survival and the CONUT score were examined. Results: The median CONUT score was found to be higher in those who had treatment indications compared to those who did not (2 vs 1; P = 0.014). In the regression model, a CONUT absolute value above 5 was found as an independent risk factor predicting relapse. In the whole study population, a CONUT absolute value >2 predicted the risk of mortality with 53.9% sensitivity and 68.7% specificity (AUC ± SE = 0.639 ± 0.07; +PV = 35%; -PV = 82.6%; P = 0.034). Conclusion: CONUT score is a predictive and prognostic factor for patients with iNHL. The development of simple, low-budget prognostic and predictive biomarkers is critical not only for determining the course of the disease but also for follow-up and treatment management.